What You Need To Know About ORPH Stock And HGEN Stock Today

Orphazyme A S ADR ORPH shares are trading lower by more than 31% Monday morning after the company's Phase 2/3 trial evaluating armioclomol for treatment of inclusion body myositis did not meet its primary and secondary endpoints.

Orphazyme is a biopharmaceutical company harnessing the amplification of Heat Shock Proteins. The company is engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative diseases.

Humanigen Inc HGEN shares are trading higher by 58% after the company's Phase 3 study of Lenzilumab achieved its primary endpoint.

Humanigen is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. 

The company primarily focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T cell therapy.